AbbVie (NY:ABBV)

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

Topics Intellectual Property

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

Why AbbVie Stock May Be the Ultimate Option for Dividend Investors ↗

March 02, 2026

AbbVie pays a high dividend, has grown its payout regularly, and has a strong underlying business.

The company is down slightly this year, but that may be a buying opportunity.

Topics Economy

Where Will AbbVie Be in 5 Years? ↗

February 26, 2026

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics Intellectual Property

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises ↗

Topics Intellectual Property

February 25, 2026

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Via Stocktwits

Topics Intellectual Property

This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income ↗

February 24, 2026

AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.

As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the...

Topics ETFs Intellectual Property

Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad

February 23, 2026

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

1 Cash-Producing Stock to Target This Week and 2 We Ignore

February 22, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Any of these three pharmaceutical titans could move the needle in your portfolio.

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Income investors can rest easy owning these stocks.

Topics Economy Intellectual Property

2 Dividend Stocks to Hold for the Next 5 Years ↗

February 19, 2026

Cash Flowing Companies that Raise Dividends

Topics Energy Intellectual Property

What's going on in today's session: S&P500 movers ↗

February 18, 2026

Via Chartmill

6 Forever Dividend Stocks ↗

February 18, 2026

Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less room for explosive growth as scale works...

1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

February 17, 2026

All 8 stocks with big upside

8 Cheap Stocks to Buy in 2026 ↗

February 16, 2026

The recent dip may have been an overreaction.

1 No-Brainer Dividend Stock to Buy on the Dip ↗

February 15, 2026

All 5 stocks look like intriguing buys

Topics Intellectual Property

5 Best Stocks to Buy in February ↗

February 15, 2026

These dividend stocks are built for the long haul.

Topics Artificial Intelligence

3 Dividend Stocks to Hold for the Next 20 Years ↗

February 15, 2026

These two stocks have historically zigged when the market has zagged.

Topics Intellectual Property

2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗

February 14, 2026

Topics Stocks

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 12, 2026, the financial landscape has undergone a tectonic shift, with the healthcare sector decisively seizing the mantle of market leadership. After years of dominance by high-flying...

Topics Artificial Intelligence ETFs Government

The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026

February 12, 2026

This Dividend King has staying power.

Topics Artificial Intelligence Bonds Economy

1 Reason I'm Never Selling AbbVie Stock ↗

February 12, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Topics Intellectual Property

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Topics Economy Intellectual Property

The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

February 11, 2026

AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded negatively, reflecting concerns over certain business segments and future...

The iShares Core High Dividend ETF is up 12% this year.

Topics Earnings

Silver and Gold Prices Are Volatile. Buy This ETF for Safety This Year ↗

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Topics ETFs

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

Via FinancialNewsMedia

3 Market-Beating Stocks to Research Further

February 08, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...